P 1075

Drug Profile

P 1075

Latest Information Update: 03 Nov 2000

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator LEO Pharma
  • Developer AstraZeneca; LEO Pharma
  • Class Anti-ischaemics; Antiarrhythmics; Antihypertensives; Guanidines; Muscle relaxants; Vasodilators
  • Mechanism of Action Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alopecia; Arrhythmias; Ischaemic heart disorders

Most Recent Events

  • 03 Nov 2000 Discontinued-II for Alopecia in Europe (Unknown route)
  • 03 Nov 2000 Discontinued-Preclinical for Arrhythmias in Sweden (Unknown route)
  • 03 Nov 2000 Discontinued-Preclinical for Ischaemic heart disorders in Sweden (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top